Please login to the form below

Not currently logged in
Email:
Password:

Raffi Asadorian joins AcelRx Pharmaceuticals

He moves from biotech firm Amyris to take up chief financial officer role

Raffi AsadorianSpeciality pharmaceutical company AcelRx Pharmaceuticals has appointed Raffi Asadorian as its new chief financial officer.

He has over 25 years’ experience in finance, strategy and corporate development and was most recently chief financial officer at commercial-stage biotech company Amyris.

Asadorian said: “This is an exciting time to join AcelRx, especially with multiple upcoming milestones in the US and EU that have the potential to transform the company.

“It’s clear that the company has an experienced management team and a robust portfolio of late stage assets. I look forward to contributing to this dynamic organisation and its growth.”

Prior to joining Amyris, Asadorian was the CFO for Asa, a private equity-owned medical diagnostics company where he led finance, corporate development and investor relations.

He has also held roles at PircewaterhouseCoopers and Barr, which was later acquired by Teva Pharmaceuticals.

Vince Angotti, chief executive officer at AcelRx, said: “I am thrilled to have Raffi join our team. He is an accomplished financial executive who has held leadership roles in large multinational, specialty pharmaceutical and life sciences companies.”

1st August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics